Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796803 | 0.88 | ADORA1 (0.55) | ADORA1KDM4EMAPTMKNK1PTGER4 | |
| SCHEMBL7794246 | 0.86 | ADORA1 (0.65) | ADORA1KDM4EMAPTMKNK1P2RX3 | |
| SCHEMBL7794276 | 0.85 | ADORA1 (0.63) | ADORA1KDM4EMAPTMKNK1PTGER4 | |
| SCHEMBL27302182 | 0.80 | ADORA1 (0.77) | ADORA1KDM4EMAPTMKNK1PTGER4 | |
| SCHEMBL6425010 | 0.79 | ADORA1 (0.55) | ADORA1KDM4EMAPTMKNK1P2RX3 | |
| SCHEMBL3499018 | 0.78 | ADORA1 (1.00) | ADORA1KDM4EMAPTMKNK1PTGER4 | |
| SCHEMBL7794277 | 0.76 | ADORA1 (0.55) | ADORA1KDM4EMAPTMKNK1P2RX3 | |
| SCHEMBL20665903 | 0.76 | ADORA1 (0.61) | ADORA1KDM4EMAPTMKNK1P2RX3 | |
| SCHEMBL13037555 | 0.75 | ADORA1 (0.75) | ADORA1KDM4EMAPTMKNK1P2RX3 | |
| SCHEMBL13736559 | 0.74 | ADORA1 (0.68) | ADORA1KDM4EMAPTMKNK1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010151317-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ADORA1 2928/4885KDM4E 903/4885MAPT 2380/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ADORA1 2928/4885KDM4E 903/4885MAPT 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.